PARIS, Sept. 6, 2011 /PRNewswire/ -- Cellectis (Alternext: ALCLS), the French genome engineering specialist, will present at the UBS Global Life Sciences Conference in New York City on September 20, 2011, and at the MidCap Event in Paris on September 22 & 23, 2011.
Marc Le Bozec, CFO, will present the activities and the development strategy of the Cellectis group at the UBS Global Life Sciences Conference at the Grand Hyatt New York hotel on Tuesday, September 20, 2011 at 11:30 am ET.
Andre Choulika, Chairman and CEO, and Marc Le Bozec, CFO, will present Cellectis at the MidCap Event at Palais Brongniart in Paris on September 22-23.
Cellectis improves life by applying its genome engineering expertise to a broad range of applications, including agriculture, bioresearch and human therapeutics. Cellectis is listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris.
For further information about Cellectis, visit our website at: www.cellectis.com
Follow Cellectis on twitter : http://twitter.com/cellectis
This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve unforeseeable risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.
Copyright©2010 PR Newswire.
All rights reserved